cnc/wcg merger close jan
introduc pro forma model combin compani
opportun gain share govern busi
acceler growth reiter top
wellcar transact opportun expand earn
potenti acceler medicar growth increas exposur pdp
market last year comment see medicar
advantag import driver futur growth membership stay
flat near member face medicar star headwind see
wellcar hand demonstr success grow star
rate enrol expand member addit
pdp member aetna member revenu anticip
contribut growth addit legaci aetna part busi
particular add attract portfolio could leverag centen
invest pbm rxadvanc see addit wellcar
medicar pdp busi combin compani revenu breakdown
medicaid market share
legaci centen medicar pdp exchang
increas insul overal entiti busi
regulatori uncertainti see contribut cnc share multipl
combin pro forma total pharmaci spend
opportun grow pbm faster pace addit option
associ renegoti wellcar contract follow
announc transact back march wellcar manag
highlight combin pharmaci spend size opportun improv
negoti leverag ahead contract renew
hand roll rxadvanc cloud-bas platform
manag standard specialti drug benefit across busi
goal transit medicaid state end
recent analyst day manag refrain discuss
opportun expect hear manag upon deal close
healthcar facil manag unit state
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
model updat reiter price target updat model
reflect complet transact ep estim
assum deal neutral earn first year line
manag guidanc driven integr cost rais
ep compar consensu
contribut accret stand-alone estim core
growth driven medicare/pdp net synergi combin
entiti swing factor earn includ new pbm deal
wellcar favor term estim
upsid addit wellcar recogn revenu aetna pdp
increment revenu price target base price-to-earnings
multipl base case ep normal hif
current trade price-to-earnings earn estim
share trade discount respect versu
discount medicar sell-off averag
discount
servic
gener administr expens
amort intang
invest incom incom
incom continu oper
 revenu
tax rate hif
net incom continu oper
multipl growth lever wcg rxadvanc execut success
calcul price target appli price-to-earnings multipl base case ep
normal hif multipl reect turn discount multipl
trade discount medicar sell
adjust repeal hif estimate turn
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
jan gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
largest medicaid player
market share
wellcar acquisit expand
market presenc medicar advantag
fastest grow market
stand-alone wellcar outperform
suggest potenti upsid deal accret
base estim break-even
mid-single-digit accret
addit upsid opportun
insourc pbm integr
medic pharmaci benet
repeal would headwind
assign low probabl outcom
view descript risk reward theme
ep plu hif
discount multipl
discount multipl
in-lin averag discount
last year medicar
advantag take exchang stabil
see multipl growth driver
potenti headwind ceas materi
due dc gridlock medicar ramp
gap medicaid group
ep plu hif
multipl
multipl trade
discount medicar
sell adjust
repeal hif estimate turn base case
core execut medicar advantag
expans top exchang protabl
ep plu hif
multipl
multipl discount in-
line stock trade
trough last price cycl
medicar advantag fail launch
becom headwind medicar
advantag stall loss core
medicaid busi fide fail reach
texa unit state constitution
view explan region hierarchi
research highest favor quintil
deal wcg drive acceler growth
margin perform high end
rxadvanc grow big market pharmaci
wcg out-performance drive upsid
loss core medicaid contract
exchang protabl less expect
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
valuat methodolog risk
ow pt calcul price target appli price-to-earnings multipl
base case ep normal hif multipl reflect turn
discount multipl trade discount
medicar sell adjust repeal hif estimate turn risk
price target includ regulatori uncertainti continu weigh sector
multipl loss core medicaid contract exchang profit less
expect risk upsid includ deal wcg drive acceler growth
medicar advantag win new medicaid contract margin perform
high end target
